You are here: Industry Insights > Market News > Pharma exports up 12.43 per cent during Apr-Dec 2021

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Pharma exports up 12.43 per cent during Apr-Dec 2021

expresspharmaFebruary 08, 2021

Tag: India , Export

Favorites

India’s exports of pharmaceutical products during April-December 2020-21 grew by 12.43 per cent to USD 17.57 billion.

India’s exports of pharma products have not declined and they are growing consistently, Minister of State for Commerce and Industry Hardeep Singh Puri said in a written reply to the Rajya Sabha.

“During 2019-20, India’s exports of pharma were USD 20.58 billion with a growth rate of 7.57 per cent over the previous year. Total pharma exports during April-December 2020-21 were at USD 17.57 billion, registering a growth rate of 12.43 per cent over the same period of the previous year,” he said.

Previous:AstraZeneca expects US trial results in next 4-6 weeks, research chief says

Next:India sent 56 L COVID-19 vaccines to foreign nations as gift;100 L doses as commercial supplies: MEA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Pharma exports up 12.43 per cent during Apr-Dec 2021 | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Professional Export Organic Seed Extract Dried Flavor Protein Water Bulk Spray Pumpkin Powder

Import and Export Service of Pharmaceutical Reagents, Chemicals, and Batteries

Instock Export Factory Supply Natural Anti-virus Ban Lan Gen Radix Isatidis Extract Powder

Customized blister box food inner tray Customized export blister tray PVC plastic box Plastic tray

Wellgreen Low Price Export Iso Certified Tannic acid Food Grade Gallic Acid Galla Chinensis Extract

Factory Free Sample Bulk Food Pure Grade Natural India Herbal Plant Extract Madder Root Extract

Chloroamphenico (export grade)

Wellgreen Factory Direct Export Food Grade Health Care Use Fennel Seeds Extract Powder

Indian Trum etflower Seed Extract

Mifepristone (INDIA DMF)

Pharma exports up 12.43 per cent during Apr-Dec 2021

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may likeMore>>

You may like
More>>